Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study

International Clinical Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 203-208

  Novick, Diego ^a   Haro, Josep Maria ^b   Suarez, David ^b   Marques Teixeira, João ^c   Naber, Dieter ^d  

^a ELI LILLY AND COMPANY   (United States)

^b Saint John of God Research and Teaching Foundation   (Spain)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotic; European Schizophrenia Outpatient Health Outcomes; Schizophrenia; Switching

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; BENZODIAZEPINE DERIVATIVE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONFIDENCE INTERVAL; DATA ANALYSIS; DRUG SUBSTITUTION; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; IMPOTENCE; LIBIDO DISORDER; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CHANGE; WEIGHT GAIN; CLINICAL TRIAL; COMPARATIVE STUDY; MULTICENTER STUDY; STATISTICAL MODEL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 54049099233     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282ff5fed     Document Type: Article

References (32)

1. Allison DB, Mackell JA, McDonnell DD (2003). The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 54:565-567.
2. Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, Garcia-Potyilla MP, Fernandez I, et al. (2003). Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 62:77-88.
3. Burns T, Christova L, Cooper S, Harrison G, McKendrick J, Laugharne R, et al. (2006). Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 113: 126-134.
4. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. (2003). Switching patients to ariprazole from other antipsychotic agents: a multi-centre randomized study. Psychopharmacology (Berl) 166:391-399.
5. De Nayer A, Windhager E, Irmansyah, Larmo I, Lindenbauer B, Rittmannsberger H, et al. (2003). Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 7:59-66.
6. Dossenbach MR, Kratky P, Schneidman M, Grudy SL, Metcalfe S, Tollefson GD, et al. (2001). Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 62 (Suppl 2):28-34.
7. Ganguli R (2002). Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 59 (22 Suppl 8):S22-S26.
8. Guy W (1976). Clinical Global Impression. In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville, Maryland: National Institute of Mental Health.
9. Haddad P (2005). Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19 (Suppl):16-27.
10. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. (2003a). The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 107:222-232.
11. Haro JM, Edgell ET, Frewer P, Alonso J, Jones PB, on behalf of the SOHO Study Group (2003b). The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 107 (Suppl 416):1-9.
12. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. (2003c). The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 107 (Suppl 416):16-23.
13. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, et al. (2007). Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17: 235-244.
14. Kane JM (2001). Extrapyramidal side effects are unacceptable. Eur Neuro-psychopharmacol 11 (Suppl 4):397-403.
15. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA (2006). Improvement in hyperpro-lactinaemia and reproductive comorbidites in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577-588.
16. Kluge M, Wehmeier PM, Dittmann RW, Langer F, Czekalla J, Lehmann M, et al. (2005). A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38:6-12.
17. Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Jones PB, et al. (2005). Olanzapine versus other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 111:232-243.
18. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. (2004). Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161 (Suppl 2):1-56.
19. Leiden PJ (2007). EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 13:13-24.
20. Leslie DL, Rosenheck RA (2002). From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. Am J Psychiatry 159:1534-1540.
21. Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003). Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 6:67-75.
22. Masand PS (2005). A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7:121-129.
23. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR (1999). Use patterns for antipsychotic medicartion in Medicaid patients with schizophrenia. J Clin Psychiatry 60 (Suppl 19):5-13.
24. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
25. Melkersson K (2005). Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 66: 761-767.
26. National Institute for Clinical Excellence (NICE) (2002). Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: NICE.
27. Rothbard AB, Kuno E, Foley K (2003). Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 29:531-540.
28. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611-622.
29. Takahashi H, Ypshida K, Ishigooka J, Higuchi H (2006). Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial. Prog Neuropsychopharmacol Biol Psychiatry 30: 1067-1072.
30. Weiden PJ (2006). Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 20:104-118.
31. Weiden PJ, Daniel DG, Simpson G, Romano SJ (2003). Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:595-600.
32. Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD (1999). Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 37 (4 Suppl):AS81-AS86.